

DAFTAR PUSTAKA

- Al Habeeb, Waleed Et Al. "Management Of End-Stage Heart Failure: A Perspective On The Arab Gulf States." *Annals Of Saudi Medicine* Vol. 29,6 (2009): 460-6.
- Aru W. Sudoyo,Dkk. (2006) *Ilmu Penyakit Dalam Fkui*. Jakarta: Pusat Penerbitan Ilmu Penyakit Dalam Fkui.
- Aune D, Sen A, Norat T, Janszky I, Romundstad P, Tonstad S, Vatten Lj. Body Mass Index, Abdominal Fatness, And Heart Failure Incidence And Mortality: A Systematic Review And Dose-Response Meta-Analysis Of Prospective Studies. *Circulation*. 2016 Feb 16;133(7):639-49.
- Bhargava V, Shabetai R, Mathiasen Ra, Dalton N, Hunter Jj, Ross J Jr. Loss Of Adrenergic Control Of The Force-Frequency Relation In Heart Failure Secondary To Idiopathic Or Ischemic Cardiomyopathy. *Am J Cardiol*. 1999;81:1130-1137.
- British Heart Foundation. 2014. *Cardiovascular Disease Statistics*: https://www.bhf.org.uk/~media/files/publications/research/bhf_cvd-statistics-2014_web_2.pdf.
- Carbone, S., Canada, J. M., Billingsley, H. E., Siddiqui, M. S., Elagizi, A., & Lavie, C. J. (2019). Obesity Paradox In Cardiovascular Disease: Where Do We Stand?. *Vascular Health And Risk Management*, Volume 15, 89–100.

- Chun S, Tu Jv, Wijeyesundera Hc, Austin Pc, Wang X, Levy D, Lee Ds. Lifetime Analysis Of Hospitalizations And Survival Of Patients Newly- Admitted With Heart Failure. *Circ Heart Fail*. May 2, 2012.
- Cox Zl, Lai P, Lewis Cm, Lindenfeld Ja. Body Mass Index And All-Cause Readmissions Following Acute Heart Failure Hospitalization. *Int J Obes*. 2020.
- Csige, I., Ujvárosy, D., Szabó, Z., Lőrincz, I., Paragh, G., Harangi, M., & Somodi, S. (2018). The Impact Of Obesity On The Cardiovascular System. *Journal Of Diabetes Research*, 2018, 1–12.
- Davis Jd, Olsen Ma, Bommarito K, Larue Sj, Saeed M, Rich Mw, Et Al. All-Payer Analysis Of Heart Failure Hospitalization 30-Day Readmission: Comorbidities Matter. *Am J Med*. 2017.
- Desai, A. S., & Stevenson, L. W. (2012). Rehospitalization For Heart Failure: Predict Or Prevent? *Circulation*, 126(4), 501–506.
- Dickstein K, Cohen-Solal A, Filippatos G, McMurray Jj, Ponikowski P, Poole-Wilson Pa, Stromberg A, Van Veldhuisen Dj, Atar D, Hoes Aw, Keren A, Mebazaa A, Nieminen M, Priori Sg, Swedberg K. Esc Guidelines For The Diagnosis And Treatment Of Acute And Chronic Heart Failure 2008: The Task Force For The Diagnosis And Treatment Of Acute And Chronic Heart Failure 2008 Of The European Society Of Cardiology. Developed In Collaboration With The Heart Failure Association Of The Esc (Hfa) And Endorsed By The European Society Of Intensive Care Medicine (Esicm), *Eur J Heart Fail*, 2008, Vol. 10 (Pg. 933-989).

- Fischer, C., Lingsma, H. F., Marang-Van De Mheen, P. J., Kringos, D. S., Klazinga, N. S., & Steyerberg, E. W. (2014). Is The Readmission Rate A Valid Quality Indicator? A Review Of The Evidence. *Plos One*, 9(11), E112282.
- Follath, F., Yilmaz, M.B., Delgado, J.F., Parissis, J.T., Porcher, R., Gayat, E., 2011, Clinical Presentation, Management And Outcomes In The Acute Heart Failure Global Survey Of Standard Treatment (Alarm-Hf), *J Intensive Care Med*, 37 (4): 19-26.
- Ford Es, Giles Wh, Dietz Wh, 2002. Prevalence Of The Metabolic Syndrome Among Us Adults. Finding From The Third National Health And Nutrition Examination Survey. *Journal American Medical Association*. 287(20): 356–59.
- Gaddam Kk, Ventura Ho, Lavie Cj. Metabolic Syndrome And Heart Failure - The Risk, Paradox, And Treatment. *Current Hypertension Reports*. 2011.
- Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., ... Jastreboff, A. M. (2016). American Association Of Clinical Endocrinologists And American College Of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care Of Patients With Obesity. *Endocrine Practice*, 22 (Supplement 3), 1–203.
- Georgiopolou Vv, Kalogeropoulos Ap, Sperling Ls, And Butler J. Chapter 10 Heart Failure Prevention In Preventive Cardiology: A Companion To Braunwald's Heart Disease 2011. 978-1-4377-1366-4.
- Gustafsson F, Kragelund Cb, Torppedrson C, Seibaek M, Burchardt H, Akkan D Et Al. Effect Of Obesity And Being Overweight On Long Term Mortality In

- Congestive Heart Failure: Influence Of Left Ventricular Systolic Function. *European Heart Journal* 2005; 26:5864.
- Gheorghide M, Abraham Wt, Albert Nm, Greenberg Bh, O'connor Cm, She L, Stough Wg, Yancy Cw, Young Jb, Fonarow Gc. Systolic Blood Pressure At Admission, Clinical Characteristics, And Outcomes In Patients Hospitalized With Acute Heart Failure. *Jama*. 2006;296: 2217–2226.
- Horwich Tb, Fonarow Gc, Clark Al. Obesity And The Obesity Paradox In Heart Failure. *Progress In Cardiovascular Diseases*. 2018.
- Indraprasta, D. 2019. Echo Heart Failure Score As 60 Days Readmission Predictor In Congestive Heart Failure Patients With Left Ventricle Systolic Dysfunction In Makassar City. Tesis. Program Pendidikan Dokter Spesialis Universitas Hasanuddin Makassar.
- Indrisa M Et Al., 2019. Penentuan Luas Otot Lengan Dan Komposisi Lemak Tubuh. Program Studi Gizi, Fakultas Kedokteran Dan Ilmu Kesehatan, Universitas Kristen Satya Wacana.
- Jensen, S. M., Mølgaard, C., Ejlerskov, K. T., Christensen, L. B., Michaelsen, K. F., & Briend, A. (2012). Validity Of Anthropometric Measurements To Assess Body Composition, Including Muscle Mass, In 3-Year-Old Children From The Skot Cohort. *Maternal & Child Nutrition*, 11(3), 398–408.
- Joseph J, P S S, James J, Abraham S, Abdullakutty J. Guideline-Directed Medical Therapy In Heart Failure Patients: Impact Of Focused Care Provided By A Heart Failure Clinic In Comparison To General Cardiology Out-Patient Department. *Egypt Hear J*. 2020.

- Kamiya, K., Masuda, T., Matsue, Y., Inomata, T., Hamazaki, N., Matsuzawa, R., ... Ako, J. (2016). Complementary Role Of Arm Circumference To Body Mass Index In Risk Stratification In Heart Failure. *Jacc: Heart Failure*, 4(4), 265–273.
- Kansagara D, Englander H, Salanitro A, Kagen D, Theobald C, Freeman M, Kripalani S. Risk Prediction Models For Hospital Readmission: A Systematic Review. *Jama*. 2011;306:1688–1698.
- Kementerian Kesehatan Republik Indonesia (Kemenkes Ri). 2013. Riset Kesehatan Dasar. Jakarta: Badan Penelitian Dan Pengembangan Kesehatan.
- Kilgore, M., Patel, H. K., Kielhorn, A., Maya, J. F. & Sharma, P. 2017. Economic Burden Of Hospitalizations Of Medicare Beneficiaries With Heart Failure. *Risk Manag Health Policy*, 10, 63-70.
- Kim Ch, Measurements Of Adiposity And Body Composition. *Korean J Obes* 2016 September;25(3):115-120.
- Klein S, Allison Db, Heymsfield Sb, Kelley De, Leibel Rl, Nonas C, Et Al. Waist Circumference And Cardiometabolic Risk: A Consensus Statement From Shaping America’s Health: Association For Weight Management And Obesity Prevention; Naaso, The Obesity Society; The American Society For Nutrition; And The American Diabetes Association. *Obesity*. 2007.
- Kociol Rd, Horton Jr, Fonarow Gc, Reyes Em, Shaw Lk, O’connor Cm, Felker Gm, Hernandez Af. Admission, Discharge, Or Change In B-Type Natriuretic Peptide And Long-Term Outcomes: Data From Organized Program To Initiate

- Lifesaving Treatment In Hospitalized Patients With Heart Failure (Optimize-Hf) Linked To Medicare Claims. *Circulation*. 2011;4:628 – 636.
- Lavie, C. J., Milani, R. V., & Ventura, H. O. (2009). Obesity And Cardiovascular Disease. *Journal Of The American College Of Cardiology*, 53(21), 1925–1932.
- Lilly, L. S. 2016, *Pathophysiology Of Heart Disease: A Collaborative Project Of Medical Student And Family*, 6th Edn, Lippincott & Wilkins, Boston.
- Liubov, Bn, Sohar, E, Laor, A 2012, ‘Neck Circumference As S Simple Screening Measure Foridentifying Overweight And Obese Patients’, *The North Association For The Study Of Obesity*, Vol. 9, No.8, Hh. 470-477.
- Luan H, Song Y, Cao L, Wang P, Zhu D, Tian G. Gender Differences In The Relationship Of Waist Circumference To Coronary Artery Lesions And One-Year Re-Admission Among Coronary Artery Disease Patients With Normal Body Mass Index. *Diabetes, Metab Syndr Obes Targets Ther*. 2021.
- Mahmood Ss, Wang Tj. The Epidemiology Of Congestive Heart Failure: The Framingham Heart Study Perspective. *Glob Heart*. 2013;8(1):77-82.
- Masson S, Anand I, Favero C, Barlera S, Vago T, Bertocchi F, Maggioni Ap, Tavazzi L, Tognoni G, Cohn Jn, Latini R. Serial Measurement Of Cardiac Troponin T Using A Highly Sensitive Assay In Patients With Chronic Heart Failure: Data From 2 Large Randomized Clinical Trials. *Circulation*. 2012;125:280 –288.

- Nishikido, T., Oyama, J., Nagatomo, D., & Node, K. (2018). A Reduction Of Bmi Predicts The Risk Of Rehospitalization And Cardiac Death In Non-Obese Patients With Heart Failure. *International Journal Of Cardiology*.
- O'connor Cm Et Al. 2010. Causes Of Death And Rehospitalization In Patients Hospitalized With Worsening Heart Failure And Reduce Left Ventricular Ejection Fraction: Results From Efficacy Of Vasopressin Antagonism In Heart Failure Outcome Study With Tolvaptan (Everest) Program. *Am Heart J*. 5;159:841-849.
- Oreopoulos A, Ezekowitz Ja, Mcalister Fa, Kalantar-Zadeh K, Fonarow Gc, Norris Cm, Et Al. Association Between Direct Measures Of Body Composition And Prognostic Factors In Chronic Heart Failure. *Mayo Clin Proc*. 2010.
- Oreopoulos A, Padwal R, Kalantarzadeh K, Fonarow Gc, Norris Cm, Mcalister Fa. Body Mass Index And Mortality In Heart Failure: A Metaanalysis. *Am Heart J* 2008; 156:1322.
- Ortega, F. B., Lavie, C. J., & Blair, S. N. (2016). Obesity And Cardiovascular Disease. *Circulation Research*, 118(11), 1752–1770.
- Page, J. H., Rexrode, K. M., Hu, F., Albert, C. M., Chae, C. U., & Manson, J. E. (2009). Waist-Height Ratio As A Predictor Of Coronary Heart Disease Among Women. *Epidemiology*, 20(3), 361–366.
- Perrone-Filardi P, Paolillo S, Costanzo P, Savarese G, Trimarco B, Bonow Ro. The Role Of Metabolic Syndrome In Heart Failure. *European Heart Journal*. 2015.

- Persatuan Ahli Gizi Indonesia. (2009). Tabel Komposisi Pangan Indonesia. Jakarta: Pt. Elex Media Komputindo.
- Perhimpunan Rumah Sakit Seluruh Indonesia (Persi), 2020. White Paper. Optimalisasi Koding Ina-Cbgs Untuk Prosedur Jantung Intervensi Dan Invasive Di Era Jkn. <https://Persi.Or.Id/White-Paper-Optimalisasi-Koding-Ina-Cbgs-Untuk-Prosedur-Jantung-Intervensi-Dan-Invasive-Di-Era-Jkn/>.
- Ravensbergen, H., Rianne, J.C., Lear, S.A., & Claydon, V.E. (2014). Waist Circumference Is The Best Index For Obesity-Related Cardiovascular Disease Risk In Individuals With Spinal Cord Injury. *Journal Of Neurotrauma*, 31(3), 292–300.
- Razi, Syed & Manish, Gutch & Keshav, Gupta & Sukriti, Kumar & Gupta, Abhinav. (2016). Site Or Size Of Waist Circumference, Which One Is More Important In Metabolic Syndrome?. *International Journal Of Medicine And Public Health*. 6. 69-72. 10.5530/Ijmedph.2016.2.4.
- Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern Sm, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, Mcdermott M, Meigs J, Moy C, Nichol G, O'donnell C, Roger V, Sorlie P, Stein- Berger J, Thom T, Wilson M, Hong Y. Heart Disease And Stroke Statistics–2008 Update: A Report From The American Heart Association Statistics Committee And Stroke Statistics Subcommittee. *Circulation*. 2008; 117:E25– E146.
- Rosenbaum, L. The Untold Toll—The Pandemic's Effects On Patients Without Covid-19. *New England Journal Of Medicine*, 2020;382(24).


- Ross R, Neeland Ij, Yamashita S, Shai I, Seidell J, Magni P, Et Al. Waist Circumference As A Vital Sign In Clinical Practice: A Consensus Statement From The Ias And Iccr Working Group On Visceral Obesity. *Nat Rev Endocrinol*. 2020.
- Russo Mj, Gelijns Ac, Stevenson Lw, Sampat B, Aaronson Kd, Renlund Dg, Ascheim Dd, Hong Kn, Oz Mc, Moskowitz Aj, Rose Ea, Miller Lw. The Cost Of Medical Management In Advanced Heart Failure During The Final Two Years Of Life. *J Card Fail*. 2008;14:651–658.
- Sandjaja. (2010). *Gizi*, Jakarta: Pt Kompas Media Nusantara.
- Stevenson Lw, Zile M, Bennett Td, Kueffer Fj, Jessup Ml, Adamson P, Abraham Wt, Manda V, Bourge Rc. Chronic Ambulatory Intracardiac Pressures And Future Heart Failure Events. *Circulation*. 2010;3:580–587.
- Sun Y, Liu B, Snetselaar Lg, Wallace Rb, Caan Bj, Rohan Te, Et Al. Association Of Normal-Weight Central Obesity With All-Cause And Cause-Specific Mortality Among Postmenopausal Women. *Jama Netw Open*. 2019.
- Supariasa, I.D.N. Dkk. (2014). *Penilaian Status Gizi (Edisi Revisi)*. Jakarta : Buku Kedokteran Egc.
- Suryajaya, Pi (2021). *Peranan Parameter Fungsi Diastolik Ventrikel Kiri Berbasis Doppler Dan Parameter Echo Heart Failure Score Sebagai Prediktor Readmisi Terkait Gagal Jantung Sistolik Dengan Ejeksi Fraksi Rendah*. Thesis-S2 Thesis, Universitas Hasanuddin.
- Timby Bk. (2009). *Fundamentals Nursing Skills Dan Concepts*. 9th Ed. Philadelphia; Lippincott Willian And Witkins.

- Tolonen, A., Pakarinen, T., Sassi, A., Kyttä, J., Cancino, W., Rinta-Kiikka, I., ... Arponen, O. (2021). Methodology, Clinical Applications, And Future Directions Of Body Composition Analysis Of Computed Tomography (Ct) Images: A Review. *European Journal Of Radiology*, 109943.
- Van Dis I, Kromhout D, Geleijnse Jm, Boer Jma, Verschuren Wmm. Body Mass Index And Waist Circumference Predict Both 10-Year Nonfatal And Fatal Cardiovascular Disease Risk: Study Conducted In 20 000 Dutch Men And Women Aged 20-65 Years. *Eur J Cardiovasc Prev Rehabil*. 2009.
- Wengkang, Y.A.S. 2018. Echo Heart Failure Score As A Short -Term Rehospitalization Predictor In Congestive Heart Failure Patients With Left Ventricle Systolic Dysfunction In Makassar City. Tesis. Program Pendidikan Dokter Spesialis Universitas Hasanuddin Makassar.
- Who. (2012). World Health Statistic: https://www.who.int/gho/publications/world_health_statistics/2014/en/.
- Wiley Jf, Chan Y-K, Ahamed Y, Ball J, Carrington Mj, Riegel B, Et Al. Multimorbidity And The Risk Of All-Cause 30-Day Readmission In The Setting Of Multidisciplinary Management Of Chronic Heart Failure. *J Cardiovasc Nurs* [Internet]. 2018 Sep;33(5):437–45. Available From: <https://journals.lww.com/00005082-201809000-00008>.
- World Health Organization. 2000. Obesity: Preventing And Managing The Global Epidemic. Geneva: Who.

Yip, Connie Et Al. "Imaging Body Composition In Cancer Patients: Visceral Obesity, Sarcopenia And Sarcopenic Obesity May Impact On Clinical Outcome." *Insights Into Imaging* Vol. 6,4 (2015): 489-97.

Yoon Hj, Ahn Y, Kim Kh, Park Jc, Choi Dj, Han S, Et Al. The Prognostic Implication Of Metabolic Syndrome In Patients With Heart Failure. *Korean Circ J.* 2013.

LAMPIRAN



KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN KESEHATAN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari, M.Med, Ph.D, Sp.GK. TELP. 081241850858, 0411 5780103. Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 307/UN4.6.4.5.31/ PP36/ 2020

Tanggal: 30 April 2021

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH21030131	No Sponsor Protokol	
Peneliti Utama	dr. Maya Shofia	Sponsor	
Judul Peneliti	OBESITAS SEBAGAI PREDIKTOR READMISI PADA PASIEN GAGAL JANTUNG SISTOLIK		
No Versi Protokol	1	Tanggal Versi	16 April 2021
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RS Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 30 April 2021 sampai 30 April 2022	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda Tangan 	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)		

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laport SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Jenis Kelamin

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Laki-laki	126	64.9	64.9	64.9
Perempuan	68	35.1	35.1	100.0
Total	194	100.0	100.0	

Outcome

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Readmisi	102	52.6	52.6	52.6
Tidak Readmisi	92	47.4	47.4	100.0
Total	194	100.0	100.0	

Etiologi_PJK

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Ya	137	70.6	70.6	70.6
Tidak	57	29.4	29.4	100.0
Total	194	100.0	100.0	

Etiologi_HT

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Ya	20	10.3	10.3	10.3
Tidak	174	89.7	89.7	100.0
Total	194	100.0	100.0	

Etiologi_Katup

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Ya	27	13.9	13.9	13.9
Tidak	167	86.1	86.1	100.0
Total	194	100.0	100.0	

Etiologi_kardiomiopati

	Frequency	Percent	Valid Per- cent	Cumulative Percent
Valid Ya	12	6.2	6.2	6.2
Tidak	182	93.8	93.8	100.0
Total	194	100.0	100.0	

Komorbid_Aritmia

	Frequency	Percent	Valid Per- cent	Cumulative Percent
Valid Ya	61	31.4	31.4	31.4
Tidak	133	68.6	68.6	100.0
Total	194	100.0	100.0	

Komorbid_DM

	Frequency	Percent	Valid Per- cent	Cumulative Percent
Valid Ya	56	28.9	28.9	28.9
Tidak	138	71.1	71.1	100.0
Total	194	100.0	100.0	

Komorbid_Ginjal

	Frequency	Percent	Valid Per- cent	Cumulative Percent
Valid Ya	47	24.2	24.2	24.2
Tidak	147	75.8	75.8	100.0
Total	194	100.0	100.0	

Komorbid_Elektrolit

	Frequency	Percent	Valid Per- cent	Cumulative Percent
Valid Ya	43	22.2	22.2	22.2
Tidak	151	77.8	77.8	100.0
Total	194	100.0	100.0	

Komorbid Infeksi

	Frequency	Percent	Valid Per- cent	Cumulative Percent
Valid Ya	53	27.3	27.3	27.3
Tidak	141	72.7	72.7	100.0
Total	194	100.0	100.0	

Sindroma metabolik

	Frequency	Percent	Valid Per- cent	Cumulative Percent
Valid Yes	140	72.2	72.2	72.2
No	54	27.8	27.8	100.0
Total	194	100.0	100.0	

NYHA

	Frequency	Percent	Valid Per- cent	Cumulative Percent
Valid II	5	2.6	2.6	2.6
III	165	85.1	85.1	87.6
IV	24	12.4	12.4	100.0
Total	194	100.0	100.0	

Furosemid

	Frequency	Percent	Valid Per- cent	Cumulative Percent
Valid Ya	194	100.0	100.0	100.0

ACE/ARB

	Frequency	Percent	Valid Per- cent	Cumulative Percent
Valid ya	133	68.6	68.6	68.6
Tidak	61	31.4	31.4	100.0
Total	194	100.0	100.0	

Beta_Blocker

	Frequency	Percent	Valid Per- cent	Cumulative Percent
Valid Ya	76	39.2	39.2	39.2
Tidak	118	60.8	60.8	100.0
Total	194	100.0	100.0	

Spirololakton

	Frequency	Percent	Valid Per- cent	Cumulative Percent
Valid Ya	90	46.4	46.4	46.4
Tidak	104	53.6	53.6	100.0
Total	194	100.0	100.0	

Digoksin

	Frequency	Percent	Valid Per- cent	Cumulative Percent
Valid Ya	63	32.5	32.5	32.5
Tidak	131	67.5	67.5	100.0
Total	194	100.0	100.0	

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Devia- tion
Usia	194	18	82	54.52	12.434
Berat Badan	194	40.0	90.3	60.420	10.6049
Tinggi_badan	194	107	179	159.90	9.088
IMT	194	18.5	35.0	23.595	3.3659
Lingkar ping- gang	194	68.5	110.0	91.781	9.5276
LILA	194	19.50	38.00	28.2160	3.67449
Platelet	194	32	648	258.45	97.930
BSA	194	1.02	2.09	1.6287	.18374
LVEF	194	14.0	39.1	26.090	6.3215
eGFR	194	3.0	156.0	77.391	33.3140
WBC	194	3.5	26.4	10.275	4.0852
HCT	194	11.0	86.0	39.011	9.4624
Hb	194	3.7	414.7	15.178	29.0220
RBC	194	1.55	12.90	4.5731	1.06745
Ureum	194	3	293	53.71	44.103
Kreatinin	194	.30	16.37	1.4240	1.42379

Natrium	194	111	150	137.51	4.926
Kalium	194	2.9	7.5	4.167	.6283
Chlorida	194	1	117	103.17	11.638
Valid N (list-wise)	194				

Binary Logistics Antopometri to Outcome

Variables in the Equation

	B	S.E.	Wald	df	Sig.	Exp(B)	95% C.I. for EXP(B)	
							Lower	Upper
IMT	.137	.068	4.062	1	.044	1.147	1.004	1.311
Lingkar pinggang	-.109	.022	24.104	1	.000	.896	.858	.936
LILA	.073	.056	1.685	1	.194	1.076	.964	1.201
Constant	4.660	1.667	7.817	1	.005	105.597		

a. Variable(s) entered on step 1: Indeks_massa_tubuh, Waist_circumference, Lingkar_lengan_atas.

Uji Etiologi terhadap IMT (K-independent)

Test Statistics^{a,b}

			Etiologi_PJK	Etiologi_HT	Etiologi_Katup	Etiologi_kardiomiopati
Chi-Square			.800	6.017	8.081	.034
Df			1	1	1	1
Asymp. Sig.			.371	.014	.004	.853
Monte Carlo Sig.			.403 ^c	.022 ^c	.006 ^c	1.000 ^c
	95% Confidence Interval	Lower Bound	.394	.019	.004	1.000
		Upper Bound	.413	.025	.007	1.000

a. Kruskal Wallis Test

b. Grouping Variable: IMT_Kategorik

c. Based on 10000 sampled tables with starting seed 2000000.

Uji Etiologi terhadap Lingkar Pinggang (K-independent)

Test Statistics^{a,b}

			Etiolo- gi_PJK	Etiolo- gi_HT	Etiologi_Katup	Etiolo- gi_kardiomiopati
Chi-Square			.285	1.943	8.855	.461
df			1	1	1	1
Asymp. Sig.			.594	.163	.003	.497
Monte Carlo	Sig.		.623 ^c	.215 ^c	.004 ^c	.557 ^c
Sig.	95% Confidence	Lower	.614	.207	.003	.548
	Interval	Bound				
		Upper	.632	.223	.005	.567
		Bound				

a. Kruskal Wallis Test

b. Grouping Variable: Waist_Circumference_Kategorik

c. Based on 10000 sampled tables with starting seed 624387341.

Uji Etiologi terhadap LILA (K-independent)


Test Statistics^{a,b}

			Etiolo- gi_PJK	Etiolo- gi_HT	Etiolo- gi_Katup	Etiolo- gi_kardiomiopati
Chi-Square			.580	.887	3.675	.114
df			1	1	1	1
Asymp. Sig.			.446	.346	.055	.735
Monte Carlo	Sig.		.467 ^c	.489 ^c	.090 ^c	1.000 ^c
Sig.	95% Confidence	Lower	.458	.479	.084	1.000
	Interval	Bound				
		Upper	.477	.498	.096	1.000
		Bound				

a. Kruskal Wallis Test

b. Grouping Variable: LLA_Kategorik

c. Based on 10000 sampled tables with starting seed 957002199.



Area Under the Curve

Test Result Variable(s)	Area	Std. Error ^a	Asymptotic Sig. ^b	Asymptotic 95% Confidence Interval	
				Lower Bound	Upper Bound
IMT	.492	.042	.853	.410	.575
Lingkar pinggang	.687	.039	.000	.611	.762
LILA	.478	.042	.592	.396	.559

The test result variable(s): Indeks_massa_tubuh, Waist_circumference, Lingkar_lengan_atas has at least one tie between the positive actual state group and the negative actual state group. Statistics may be biased.

a. Under the nonparametric assumption

b. Null hypothesis: true area = 0.5

IMT_Kategorik

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid ≤25	134	69.1	69.1	69.1
>25	60	30.9	30.9	100.0
Total	194	100.0	100.0	

Lingkar Pinggang_Kategorik

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Di atas normal	128	66	66	66
Di bawah normal	66	34	34	100.0
Total	194	100.0	100.0	

LILA_Kategorik

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid ≥23.5	172	88.7	88.7	88.7
<23.5	22	11.3	11.3	100.0
Total	194	100.0	100.0	

Coordinates of the Curve

Test Result Variable(s)	Positive if Greater Than or Equal To ^a	Sensitivity	1 - Specificity
IMT	17.500	1.000	1.000
	18.550	.990	.957
	18.650	.980	.957
	18.850	.971	.935
	19.015	.971	.902
	19.065	.961	.902

	19.215	.941	.870
	19.365	.941	.859
	19.450	.941	.848
	19.600	.931	.848
	19.750	.931	.837
	19.820	.922	.837
	19.870	.912	.837
	19.950	.902	.837
	20.050	.882	.826
	20.150	.873	.826
	20.300	.853	.815
	20.500	.853	.793
	20.700	.843	.793
	20.805	.824	.761
	20.855	.824	.750
	20.930	.804	.739
	20.980	.794	.739
	21.050	.755	.739
	21.180	.735	.739
	21.280	.725	.739
	21.400	.706	.739
	21.550	.686	.739
	21.650	.676	.717
	21.750	.657	.717
	21.825	.647	.717
	21.925	.637	.717
	22.050	.608	.674
	22.150	.608	.652
	22.250	.608	.609
	22.350	.588	.576
	22.500	.578	.576
	22.650	.559	.576
	22.750	.539	.576
	22.845	.539	.565
	22.895	.529	.565
	22.950	.520	.543
	23.100	.520	.533
	23.250	.490	.511
	23.350	.480	.478
	23.450	.451	.446

	23.550	.451	.435
	23.650	.441	.413
	23.750	.431	.413
	23.850	.422	.413
	23.950	.382	.402
	24.050	.373	.391
	24.130	.373	.380
	24.180	.363	.380
	24.300	.343	.380
	24.450	.343	.370
	24.550	.333	.359
	24.750	.314	.359
	24.905	.294	.359
	24.955	.294	.348
	25.050	.284	.315
	25.150	.284	.293
	25.250	.284	.272
	25.350	.255	.272
	25.450	.235	.250
	25.565	.225	.250
	25.665	.216	.250
	25.750	.196	.228
	25.900	.196	.217
	26.050	.186	.217
	26.200	.176	.217
	26.350	.167	.217
	26.450	.157	.217
	26.550	.157	.196
	26.750	.147	.185
	26.950	.137	.185
	27.030	.127	.174
	27.080	.118	.174
	27.220	.108	.174
	27.370	.098	.174
	27.450	.098	.152
	27.550	.088	.152
	27.700	.078	.152
	27.850	.069	.141
	27.950	.069	.130
	28.100	.069	.120

Lingkar pinggang	28.230	.059	.109
	28.280	.059	.098
	28.550	.049	.098
	28.850	.049	.076
	29.100	.039	.076
	29.600	.039	.054
	30.300	.039	.043
	31.050	.029	.043
	31.890	.020	.043
	32.440	.010	.043
	32.900	.000	.043
	34.100	.000	.022
	34.950	.000	.011
	36.000	.000	.000
	67.500	1.000	1.000
	69.000	1.000	.989
	69.750	1.000	.967
	70.750	1.000	.946
	73.000	.980	.924
	74.750	.961	.924
	75.750	.961	.913
	76.750	.951	.913
	77.500	.941	.913
	78.250	.941	.859
	78.750	.941	.848
	79.500	.931	.783
	80.250	.922	.772
	80.750	.912	.772
	81.250	.912	.761
	81.750	.912	.750
	82.250	.902	.739
	82.750	.892	.739
	83.250	.882	.707
	83.750	.882	.685
	84.250	.882	.652
	84.750	.863	.641
	85.250	.853	.620
	85.750	.843	.620
	86.250	.833	.587
	86.750	.833	.576
87.250	.833	.543	
87.750	.824	.543	
88.250	.784	.489	
88.750	.784	.478	

	89.150	.755	.435
	89.500	.745	.435
	89.850	.735	.435
	90.250	.725	.424
	90.600	.716	.424
	90.850	.706	.413
	91.100	.696	.413
	91.500	.696	.402
	91.900	.686	.402
	92.500	.657	.380
	93.500	.598	.337
	94.200	.569	.315
	94.700	.559	.315
	95.500	.549	.293
	96.250	.529	.272
	96.750	.520	.250
	97.500	.520	.207
	98.400	.402	.152
	98.900	.373	.152
	99.250	.343	.130
	99.750	.324	.130
	100.100	.235	.120
	100.500	.225	.120
	100.900	.225	.109
	101.400	.206	.109
	101.900	.196	.109
	102.400	.147	.076
	102.900	.147	.065
	103.500	.098	.054
	104.400	.088	.054
	104.900	.078	.054
	105.500	.039	.043
	106.250	.029	.022
	106.750	.020	.022
	107.500	.010	.022
	108.500	.010	.011
	109.500	.000	.011
	111.000	.000	.000
LILA	18.5000	1.000	1.000
	19.7500	.990	.978
	20.5000	.990	.967
	21.2500	.980	.957
	21.7500	.971	.946
	22.2500	.951	.946
	22.7500	.912	.924

	23.1000	.892	.902
	23.3500	.892	.880
	23.7500	.873	.859
	24.2500	.843	.848
	24.6500	.833	.848
	24.9000	.824	.848
	25.1000	.794	.815
	25.3500	.794	.804
	25.7500	.775	.804
	26.2500	.725	.717
	26.7500	.706	.696
	27.2500	.598	.630
	27.6500	.588	.620
	27.9000	.578	.620
	28.1500	.461	.489
	28.3500	.451	.489
	28.4500	.441	.489
	28.6000	.441	.478
	28.7500	.422	.467
	28.9000	.402	.467
	29.2500	.363	.380
	29.7500	.324	.370
	30.1000	.206	.250
	30.3500	.196	.250
	30.6500	.186	.250
	30.9000	.176	.239
	31.2500	.147	.185
	31.7500	.147	.163
	32.2500	.127	.109
	32.7500	.118	.109
	33.5000	.088	.087
	34.5000	.049	.087
	35.4000	.020	.043
	35.8500	.010	.043
	35.9500	.010	.033
	36.4000	.010	.022
	36.9000	.010	.011
	37.5000	.010	.000
	39.0000	.000	.000

The test result variable(s): Indeks_massa_tubuh, Waist_circumference, Lingkar_lengan_atas has at least one tie between the positive actual state group and the negative actual state group.

a. The smallest cutoff value is the minimum observed test value minus 1, and the largest cutoff value is the maximum observed test value plus 1. All the other cutoff values are the averages of two consecutive ordered observed test values.